TransMedics Group, Inc. (NASDAQ:TMDX) Short Interest Down 13.3% in February

TransMedics Group, Inc. (NASDAQ:TMDX) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 9,330,000 shares, a decline of 13.3% from the February 13th total of 10,760,000 shares. Approximately 29.9% of the shares of the stock are short sold. Based on an average trading volume of 1,880,000 shares, the short-interest ratio is presently 5.0 days.

Analyst Upgrades and Downgrades

TMDX has been the subject of a number of research analyst reports. Piper Sandler cut their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Finally, Oppenheimer restated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $122.70.

Institutional Trading of TransMedics Group

Institutional investors have recently bought and sold shares of the business. Arizona State Retirement System grew its holdings in shares of TransMedics Group by 1.9% in the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company’s stock valued at $603,000 after buying an additional 184 shares during the period. National Bank of Canada FI grew its holdings in shares of TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after buying an additional 262 shares during the period. Quarry LP grew its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after buying an additional 312 shares during the period. Envestnet Portfolio Solutions Inc. grew its holdings in shares of TransMedics Group by 7.2% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company’s stock valued at $294,000 after buying an additional 317 shares during the period. Finally, Park Avenue Securities LLC grew its holdings in shares of TransMedics Group by 3.8% in the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock valued at $548,000 after buying an additional 322 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Price Performance

TMDX opened at $68.99 on Wednesday. The company has a fifty day moving average price of $68.23 and a two-hundred day moving average price of $92.06. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $177.37. The firm has a market capitalization of $2.32 billion, a PE ratio of 73.39 and a beta of 2.12.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.